APYX

Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript

Apyx Medical (APYX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago.

Apyx Medical NASDAQ: APYX reported a 9% increase in third-quarter 2026 revenue, driven by sales of its AYON body contouring system in the United States and international demand for Renuvion. The company also narrowed its full-year operating expense target while reaffirming its revenue outlook.

Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction handpiece for the AYON system in the third quarter Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla.

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) on behalf of the company's shareholders.  The investigation seeks to determine whether Apyx Medical Corporation's directors breached their fiduciary duties in connection with recent corporate actions.

CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.

CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will present at the following investor conferences: UBS Global Healthcare Conference – November 9-11, 2026 (Miami, FL) Management will participate in a fireside chat at 10:15am ET and will host one-on-one meetings with investors on Monday, November 9.

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.

CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.